OMB APPROVAL
                                                     --------------------------
                                                     OMB Number:      3235-0362
                                                     Expires:  October 31, 2001
                                                     Estimated average burden
                                                     hours per response.....1.0


                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                     FORM 5

               ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
       Section 17(a) of the Public Utility Holding Company Act of 1935 or
               Section 30(f) of the Investment Company Act of 1940

[_]  Check  this  box if no  longer  subject  to  Section  16.  Form 4 or Form 5
     obligations may continue. See Instruction 1(b).

[_]  Form 3 Transactions Reported

[_]  Form 4 Transactions Reported

________________________________________________________________________________

1.   Name and Address of Reporting Person*

     Schaber                         Christopher
- --------------------------------------------------------------------------------
   (Last)                            (First)              (Middle)

     4 Stirrup Way
- --------------------------------------------------------------------------------
                                    (Street)

     Burlington,                   New Jersey            08016
- --------------------------------------------------------------------------------
   (City)                            (State)                (Zip)
________________________________________________________________________________

2.   Issuer Name and Ticker or Trading Symbol


     Discovery Laboratories, Inc. (DSCO)
________________________________________________________________________________

3.   IRS Identification Number of Reporting Person, if an entity (Voluntary)



________________________________________________________________________________

4.   Statement for Month/Year


     12/31/99
________________________________________________________________________________

5.   If Amendment, Date of Original (Month/Year)



________________________________________________________________________________

6.   Relationship of Reporting Person(s) to Issuer
     (Check all applicable)

     [_]  Director                             [_]  10% Owner
     [X]  Officer (give title below)           [_]  Other (specify below)

          Executive Vice-President - Drug Development and
         ________________________________________________

                    Regulatory Compliance
                    _____________________
________________________________________________________________________________

7.   Individual or Joint/Group Reporting
     (check applicable line)

     [X]  Form Filed by One Reporting Person
     [_]  Form Filed by More than One Reporting Person
________________________________________________________________________________


================================================================================
           Table I -- Non-Derivative Securities Acquired, Disposed of,
                             or Beneficially Owned
================================================================================


                                                                                                 5.
                                                                                                 Amount of      6.
                                                                 4.                              Securities     Owner-
                                                                 Securities Acquired (A) or      Beneficially   ship
                                                                 Disposed of (D)                 Owned at the   Form:     7.
                                                                 (Instr. 3, 4 and 5)             End of         Direct    Nature of
                                      2.            3.           -----------------------------   Issuer's       (D) or    Indirect
1.                                    Transaction   Transaction                  (A)             Fiscal Year    Indirect  Beneficial
Title of Security                     Date (Month/  Code             Amount      or     Price    (Instr. 3      (I)       Ownership
(Instr. 3)                            Day/Year)     (Instr. 8)                   (D)             and 4)         (Instr.4) (Instr. 4)
- ------------------------------------------------------------------------------------------------------------------------------------
                                                                                                  


- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

====================================================================================================================================

*    If the form is filed by more than one  Reporting  Person,  see  Instruction
     4(b)(v).


FORM 5 (continued) Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) ================================================================================ 9. 10. Number Owner- of ship 2. Deriv- of Conver- 5. 7. ative Deriv- 11. sion Number of Title and Amount Secur- ative Nature or Derivative 6. of Underlying 8. ities Secur- of Exer- Securities Date Securities Price Bene- ity: In- cise 3. Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct Price Trans- 4. or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene- 1. of action Trans- of (D) (Month/Day/Year) Amount ative at End In- ficial Title of Deriv- Date action (Instr. 3, ---------------- or Secur- of direct Owner- Derivative ative (Month/ Code 4 and 5) Date Expira- Number ity Year (I) ship Security Secur- Day/ (Instr. ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr. (Instr. 3) ity Year) 8) (A) (D) cisable Date Title Shares 5) 4) 4) 4) - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ Stock Option $1.38 9/30/1999 M(1) A 9/30/1999 9/30/2009 Common 85,000 (right to buy) Stock - ------------------------------------------------------------------------------------------------------------------------------------ Stock Option $3.00 1/1/1999 M(2) A 1/1/1999 1/1/2009 Common 40,000 (right to buy) Stock - ------------------------------------------------------------------------------------------------------------------------------------ Stock Option $4.44 6/16/1998 M(3) A 6/16/1998 6/16/2008 Common 20,493 (right to buy) Stock - ------------------------------------------------------------------------------------------------------------------------------------ Stock Option $4.44 6/16/1998 M(4) A 6/16/1998 6/16/2008 Common 18,400 249,544 D N/A (right to buy) Stock - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ ==================================================================================================================================== Explanation of Responses: 1. The option grants are subject to repurchase by Discovery upon the occurrence of certain events relating to the market price of the common stock of Discovery, the failure of Discovery to enter into certain collaboration agreements or a sale or merger of Discovery. 2. This option becomes vested as to 25% of the option shares on the date of the grant. The remaining 75% of the option shares are vested in three equal annual installments beginning with the first year anniversary of the date of the grant. 3. The Corporation's repurchase rights shall lapse and 100% of the option shares shall vest in the event the market capitalization of the Corporation exceeds $75 million, determined over a 30 day average. 4. The Corporation's repurchase right shall lapse and 100% of the option shares shall vest in the event that the Corporation consummates a transaction having a total value of at least $20 million involving the development, clinical testing, regulatory approval, manufacturing and/or marketing of a portfolio compound. /s/ Christopher Shaber February 11, 2000 By: ---------------------------------------- ----------------------- **Signature of Reporting Person Date ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.